Chikungunya virus infections - Pipeline Insight, 2021

DelveInsights, Chikungunya virus infections - Pipeline Insight, 2021, report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Chikungunya virus infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
Global coverage

Chikungunya virus infections Understanding
Chikungunya virus infections: Overview
Chikungunya is a viral disease transmitted to humans through the bites of mosquitoes infected with the chikungunya virus. It was first described during an outbreak in southern Tanzania in 1952 and has now been identified in nearly 40 countries in Asia, Africa, Europe and, most recently, the Americas. Symptoms usually begin 4 to 8 days after a mosquito bite but can appear anywhere from 2 to 12 days. The most common symptom is an abrupt onset of fever, often accompanied by joint pain. Other symptoms include muscle pain, headache, nausea, fatigue, and rash. Severe joint pain usually lasts a few days but can persist for months or even years. Serious complications are uncommon, but atypical severe cases can cause long-term symptoms and even death, especially in older people.

"Chikungunya virus infections - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chikungunya virus infections pipeline landscape is provided which includes the disease overview and Chikungunya virus infections treatment guidelines. The assessment part of the report embraces, in depth Chikungunya virus infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chikungunya virus infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Chikungunya virus infections R&D. The therapies under development are focused on novel approaches to treat/improve Chikungunya virus infections.

Chikungunya virus infections Emerging Drugs Chapters
This segment of the Chikungunya virus infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chikungunya virus infections Emerging Drugs
VLA1553: Valneva
VLA1553 is the chikungunya vaccine candidate in Phase 3 clinical trials that targets long-term protection following the administration of a single dose. Valneva reported positive topline results from a Phase 3 pivotal trial in August 2021. The trial, involving 4,115 adults, aged 18 years and above, across 44 sites in the U.S., met its primary endpoint inducing protective CHIKV neutralizing antibody titers in 98.5% of participants 28 days after receiving a single shot. VLA1553 was also generally well tolerated among the 3,082 subjects evaluated for safety. VLA1553 has received Fast Track and Breakthrough Therapy designation from the FDA and PRIME designation from the EMA

mRNA-1944: Moderna Therapeutics
mRNA-1944 encodes a fully human IgG antibody originally isolated from B cells of a patient with a prior history of potent immunity against chikungunya infection. It is composed of two mRNAs that encode the heavy and light chains of this anti-chikungunya antibody within Modernas proprietary lipid nanoparticle (LNP) technology. Currently, it is in phase I stage of clinical trial evaluation to treat Chikungunya virus infections.
Further product details are provided in the report..

Chikungunya virus infections: Therapeutic Assessment
This segment of the report provides insights about the different Chikungunya virus infections drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Chikungunya virus infections
There are approx. 10+ key companies which are developing the therapies for Chikungunya virus infections. The companies which have their Chikungunya virus infections drug candidates in the most advanced stage, i.e. phase III include, Valneva.

Phases
DelveInsights report covers around 10+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Route of Administration
Chikungunya virus infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Parenteral
intravenous
Subcutaneous
Topical.
Molecule Type

Products have been categorized under various Molecule types such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chikungunya virus infections: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chikungunya virus infections therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chikungunya virus infections drugs.

Chikungunya virus infections Report Insights
Chikungunya virus infections Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs

Chikungunya virus infections Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
How many companies are developing Chikungunya virus infections drugs?
How many Chikungunya virus infections drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chikungunya virus infections?
What are the key collaborations (IndustryIndustry, IndustryAcademia), Mergers and acquisitions, licensing activities related to the Chikungunya virus infections therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Chikungunya virus infections and their status?
What are the key designations that have been granted to the emerging drugs?

Key Players
Valneva
Moderna Therapeutics
Immunomodulation
Ridgeback Biotherapeutics
Etubics Corporation
Themis Bioscience
FIT Biotech
Bharat Biotech
Emergex Vaccines
Emergent BioSolutions
Indian Immunologicals Ltd.
Auro Vaccines

Key Products
VLA1553
mRNA 1944
Annexin A5
Molnupiravir
MV-CHIK
FIT-103
BBV 87
VRC CHKVLP059 00 VP
Introduction
Executive Summary
Chikungunya virus infections: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Chikungunya virus infections DelveInsights Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
VLA1553: Valneva
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
Chikungunya virus vaccine: Themis Bioscience
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
Comparative Analysis
mRNA 1944: Moderna Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical and Discovery Stage Products
Comparative Analysis
Research programme: chikungunya vaccine: Emergex Vaccines
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..


Inactive Products
Comparative Analysis
Chikungunya virus infections Key Companies
Chikungunya virus infections Key Products
Chikungunya virus infections- Unmet Needs
Chikungunya virus infections- Market Drivers and Barriers
Chikungunya virus infections- Future Perspectives and Conclusion
Chikungunya virus infections Analyst Views
Chikungunya virus infections Key Companies
Appendix

List Of Tables

Table 1 Total Products for Chikungunya virus infections
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List Of Figures

Figure 1 Total Products for Chikungunya virus infections
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Chikungunya virus infections - Pipeline Insight, 2021

DelveInsights, Chikungunya virus infections - Pipeline Insight, 2021, report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Chikungunya virus infections pipeline landscape. It covers the pipeline drug

USD 1500 View Report

Chikungunya Fever - Pipeline Review, H2 2020

Chikungunya Fever - Pipeline Review, H2 2020latest Pharmaceutical and Healthcare disease pipeline guide Chikungunya Fever - Pipeline Review, H2 2020, provides an overview of the Chikungunya Fever (Infectious Disease) pipeline

USD 2000 View Report

Norovirus Infections (Infectious Disease) - Drugs in Development, 2021

Norovirus Infections (Infectious Disease) - Drugs in Development, 2021Norovirus Infections (Infectious Disease) - Drugs in Development, 2021 provides an overview of the Norovirus Infections pipeline landscape.The report provides comprehensive information

USD 2000 View Report

Polyomavirus Infections (Infectious Disease) - Drugs in Development, 2021

Polyomavirus Infections (Infectious Disease) - Drugs in Development, 2021Polyomavirus Infections (Infectious Disease) - Drugs in Development, 2021 provides an overview of the Polyomavirus Infections pipeline landscape.The report provides comprehensive information

USD 2000 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available